Sutro Biopharma, Inc.

STRO · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders2.3%

Institutions98.6%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$102.48M	$62.04M	$67.77M	$61.88M	$42.72M	$42.74M	$38.42M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$158.37M	-$238.45M	-$128.94M	-$98.52M	-$71.06M	-$55.47M	-$37.22M
Operating income as a percentage of revenue.	-154.5%	-384.3%	-190.3%	-159.2%	-166.3%	-129.8%	-96.9%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$191.09M	-$227.46M	-$119.20M	-$105.54M	-$32.13M	-$55.74M	-$35.32M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-22.49	$-2.96	$-2.35	$-2.29	$-0.99	$-2.43	$-6.13
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-22.49	$-2.96	$-2.35	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$58.13M	$190.30M	$47.25M	$30.41M	$206.15M	$4.96M	$125.30M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$173.83M	$387.21M	$406.94M	$341.41M	$394.11M	$156.37M	–
All of the company's interest-bearing borrowings, short and long term combined.	–	–	$16.27M	$25.11M	$24.55M	$9.88M	$14.72M
Everything the company owes — debt, unpaid bills, and other obligations.	$306.28M	$342.61M	$189.90M	$88.84M	$62.06M	$58.58M	–
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	-$132.45M	$44.60M	$217.05M	$252.56M	$332.05M	$97.79M	–

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$177.23M	-$191.54M	$3.55M	-$81.68M	-$67.80M	-$65.02M	$12.68M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	–	–	–	–	–	–	$1.56M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	–	–	–	–	–	–	$11.13M

	You	Peer avg
Revenue Growth	-84.6%	+1381.4%
ROE	–	-53.9%

Sutro Biopharma, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison